ZA202403360B - Lipid nanoparticles for oligonucleotide delivery - Google Patents
Lipid nanoparticles for oligonucleotide deliveryInfo
- Publication number
- ZA202403360B ZA202403360B ZA2024/03360A ZA202403360A ZA202403360B ZA 202403360 B ZA202403360 B ZA 202403360B ZA 2024/03360 A ZA2024/03360 A ZA 2024/03360A ZA 202403360 A ZA202403360 A ZA 202403360A ZA 202403360 B ZA202403360 B ZA 202403360B
- Authority
- ZA
- South Africa
- Prior art keywords
- lipid nanoparticles
- lipid
- oligonucleotide delivery
- formula
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21205904 | 2021-11-02 | ||
| EP22179399 | 2022-06-16 | ||
| PCT/EP2022/080581 WO2023078950A1 (en) | 2021-11-02 | 2022-11-02 | Lipid nanoparticles for oligonucleotide delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202403360B true ZA202403360B (en) | 2025-08-27 |
Family
ID=84364268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2024/03360A ZA202403360B (en) | 2021-11-02 | 2024-04-30 | Lipid nanoparticles for oligonucleotide delivery |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250236599A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4426270B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024540108A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099377A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022381463A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3236653A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4426270T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3042660T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4426270T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312432B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005109A (cg-RX-API-DMAC7.html) |
| PL (1) | PL4426270T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023078950A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202403360B (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12678515B2 (en) | 2015-12-30 | 2026-07-14 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| CA3116576A1 (en) | 2018-10-18 | 2020-04-23 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| JP2025538515A (ja) * | 2022-11-25 | 2025-11-28 | 艾斯拓康医薬科技(北京)有限公司 | イオン化脂質及びその応用 |
| JP2025534494A (ja) * | 2022-12-23 | 2025-10-15 | グリーン・クロス・コーポレイション | イオン化可能な脂質及びその使用 |
| CN119219539A (zh) * | 2023-06-29 | 2024-12-31 | 艾斯拓康医药科技(北京)有限公司 | 可离子化脂质及其应用 |
| WO2025088152A1 (en) | 2023-10-27 | 2025-05-01 | Ziphius Nv | MODIFIED 5'UTRs |
| US12599560B2 (en) | 2023-11-02 | 2026-04-14 | Longuide Biopharma Corporation | Lipids and lipid nanoparticle formulations |
| AU2024381228A1 (en) | 2023-11-13 | 2026-05-28 | Ziphius Nv | MODIFIED ALPHAVIRAL nsP3 |
| WO2025128696A1 (en) * | 2023-12-12 | 2025-06-19 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025255534A1 (en) * | 2024-06-07 | 2025-12-11 | Innovac Therapeutics Hk Limited | Diol-based novel ionizable lipids and their uses thereof |
| WO2026112559A1 (en) * | 2024-11-25 | 2026-05-28 | Genzyme Corporation | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
| WO2026117525A1 (en) * | 2024-11-26 | 2026-06-04 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| PT1751289E (pt) | 2004-05-18 | 2009-03-31 | Alphavax Inc | Vectores de alfavirais derivados da tc-83, partículas e métodos |
| US7332322B2 (en) | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| WO2014028487A1 (en) * | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| CA2953341C (en) * | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| KR20190093816A (ko) * | 2016-10-26 | 2019-08-26 | 큐어백 아게 | 지질 나노입자 mRNA 백신 |
| EP3638678B1 (en) * | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
-
2022
- 2022-11-02 MX MX2024005109A patent/MX2024005109A/es unknown
- 2022-11-02 AU AU2022381463A patent/AU2022381463A1/en active Pending
- 2022-11-02 WO PCT/EP2022/080581 patent/WO2023078950A1/en not_active Ceased
- 2022-11-02 ES ES22813505T patent/ES3042660T3/es active Active
- 2022-11-02 CA CA3236653A patent/CA3236653A1/en active Pending
- 2022-11-02 JP JP2024525411A patent/JP2024540108A/ja active Pending
- 2022-11-02 KR KR1020247018058A patent/KR20240099377A/ko active Pending
- 2022-11-02 PL PL22813505.9T patent/PL4426270T3/pl unknown
- 2022-11-02 EP EP22813505.9A patent/EP4426270B1/en active Active
- 2022-11-02 IL IL312432A patent/IL312432B2/en unknown
- 2022-11-02 EP EP25189933.2A patent/EP4613741A3/en not_active Withdrawn
- 2022-11-02 FI FIEP22813505.9T patent/FI4426270T3/fi active
- 2022-11-02 US US18/705,479 patent/US20250236599A1/en active Pending
- 2022-11-02 DK DK22813505.9T patent/DK4426270T3/da active
-
2024
- 2024-04-30 ZA ZA2024/03360A patent/ZA202403360B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL312432B1 (en) | 2026-01-01 |
| PL4426270T3 (pl) | 2025-11-24 |
| EP4426270B1 (en) | 2025-07-23 |
| IL312432B2 (en) | 2026-05-01 |
| EP4613741A2 (en) | 2025-09-10 |
| WO2023078950A1 (en) | 2023-05-11 |
| EP4613741A3 (en) | 2025-11-12 |
| CA3236653A1 (en) | 2023-05-11 |
| US20250236599A1 (en) | 2025-07-24 |
| JP2024540108A (ja) | 2024-10-31 |
| IL312432A (en) | 2024-06-01 |
| ES3042660T3 (en) | 2025-11-24 |
| KR20240099377A (ko) | 2024-06-28 |
| MX2024005109A (es) | 2024-05-31 |
| DK4426270T3 (da) | 2025-09-22 |
| EP4426270A1 (en) | 2024-09-11 |
| FI4426270T3 (fi) | 2025-09-12 |
| AU2022381463A1 (en) | 2024-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005109A (es) | Nanoparticulas lipidicas para administracion de oligonucleotidos. | |
| ZA202403337B (en) | Lipid nanoparticles for oligonucleotide delivery | |
| ZA202309527B (en) | Ionizable lipids and compositions for nucleic acid delivery | |
| BR112022013599A2 (pt) | Nanomateriais | |
| MX2024007720A (es) | Lipidos para la administracion de agentes activos en nanoparticulas lipidicas. | |
| ZA202306901B (en) | Ionizable lipids | |
| AU2016343803A8 (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| EP4420679A3 (en) | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| ZA202103233B (en) | Lipid nanoparticle formulations | |
| WO2023114943A3 (en) | Lipids for use in lipid nanoparticle formulations | |
| EP4310075A3 (en) | Ionizable cationic lipid for rna delivery | |
| PH12021550701A1 (en) | Ionizable amine lipids | |
| EP4344702A3 (en) | Pyrazolyl derivatives useful as anti-cancer agents | |
| WO2019036008A8 (en) | Lipids for use in lipid nanoparticle formulations | |
| WO2023114937A3 (en) | Fluorinated cationic lipids for use in lipid nanoparticles | |
| MX2024015149A (es) | Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos | |
| MX2020000268A (es) | Agonista de fxr. | |
| MX2024005714A (es) | Lípidos catiónicos ionizables para la administración de arn. | |
| EP4410317A3 (en) | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| MX2025002671A (es) | Lipidos para uso en formulaciones de nanoparticulas de lipidos | |
| WO2015184256A3 (en) | Biodegradable lipids for delivery of nucleic acids | |
| MX2019000566A (es) | Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña. | |
| MX2012007450A (es) | Lipidos, composiciones de lipido, y metodos de uso de los mismos. | |
| EP3693369A3 (en) | Bromodomain inhibitors | |
| MX338685B (es) | Formulaciones de solucion intravenosa de posaconacol estabilizadas mediante beta-ciclodextrina sustituida. |